BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, Mui BL, Albelda SM, Puré E, June CH, Aghajanian H, Weissman D, Parhiz H, Epstein JA. CAR T cells produced in vivo to treat cardiac injury. Science 2022;375:91-6. [PMID: 34990237 DOI: 10.1126/science.abm0594] [Cited by in Crossref: 97] [Cited by in F6Publishing: 89] [Article Influence: 97.0] [Reference Citation Analysis]
Number Citing Articles
1 Xiao Y, Feng Q, Huang L, Meng X, Han P, Zhang W, Kang YJ. Copper promotes cardiac functional recovery via suppressing the transformation of fibroblasts to myofibroblasts in ischemia-infarcted monkey hearts. The Journal of Nutritional Biochemistry 2023;111:109180. [DOI: 10.1016/j.jnutbio.2022.109180] [Reference Citation Analysis]
2 . Human vaccines & immunotherapeutics news: January 2022. Hum Vaccin Immunother 2022;18:2039552. [PMID: 35275801 DOI: 10.1080/21645515.2022.2039552] [Reference Citation Analysis]
3 Macdonald KN, Salim K, Levings MK. Manufacturing next-generation regulatory T-cell therapies. Current Opinion in Biotechnology 2022;78:102822. [DOI: 10.1016/j.copbio.2022.102822] [Reference Citation Analysis]
4 Xie S, Chen M, Fang W, Liu S, Wu Q, Liu C, Xing Y, Shi W, Xu M, Zhang M, Chen S, Zeng X, Wang S, Deng W, Tang Q. Diminished arachidonate 5-lipoxygenase perturbs phase separation and transcriptional response of Runx2 to reverse pathological ventricular remodeling. eBioMedicine 2022;86:104359. [DOI: 10.1016/j.ebiom.2022.104359] [Reference Citation Analysis]
5 Wang X, Wu DH, Senyo SE. mRNA therapy for myocardial infarction: A review of targets and delivery vehicles. Front Bioeng Biotechnol 2022;10. [DOI: 10.3389/fbioe.2022.1037051] [Reference Citation Analysis]
6 Lim WA. The emerging era of cell engineering: Harnessing the modularity of cells to program complex biological function. Science 2022;378:848-852. [DOI: 10.1126/science.add9665] [Reference Citation Analysis]
7 Irvine DJ, Maus MV, Mooney DJ, Wong WW. The future of engineered immune cell therapies. Science 2022;378:853-858. [DOI: 10.1126/science.abq6990] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Biederstädt A, Manzar GS, Daher M. Multiplexed engineering and precision gene editing in cellular immunotherapy. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1063303] [Reference Citation Analysis]
9 Parv K, Hidalgo CH, Xu F, Amoedo-leite C, Giraud A, Holl D, Seignez C, Goeritz C, Christoffersson G, Phillipson M. Macrophages support healing of ischemic injury by transdifferentiating towards mural cells and adopting functions important for vascular support.. [DOI: 10.21203/rs.3.rs-2263892/v1] [Reference Citation Analysis]
10 Tsai H, Pietrobon V, Peng M, Wang S, Zhao L, Marincola FM, Cai Q. Current strategies employed in the manipulation of gene expression for clinical purposes. J Transl Med 2022;20:535. [DOI: 10.1186/s12967-022-03747-3] [Reference Citation Analysis]
11 Sciascia S, Cozzi M, Barinotti A, Radin M, Cecchi I, Fenoglio R, Mancardi D, Wilson Jones G, Rossi D, Roccatello D. Renal Fibrosis in Lupus Nephritis. IJMS 2022;23:14317. [DOI: 10.3390/ijms232214317] [Reference Citation Analysis]
12 Van Linthout S, Volk H. Immuno-cardio-oncology: Killing two birds with one stone? Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1018772] [Reference Citation Analysis]
13 Ilic D, Liovic M. Industry updates from the field of stem cell research and regenerative medicine in September 2022. Regenerative Medicine 2022. [DOI: 10.2217/rme-2022-0186] [Reference Citation Analysis]
14 Pesce M, Duda GN, Forte G, Girao H, Raya A, Roca-cusachs P, Sluijter JPG, Tschöpe C, Van Linthout S. Cardiac fibroblasts and mechanosensation in heart development, health and disease. Nat Rev Cardiol 2022. [DOI: 10.1038/s41569-022-00799-2] [Reference Citation Analysis]
15 Gabandé‐rodríguez E, Pfeiffer M, Mittelbrunn M. Immuno(T)herapy for age‐related diseases. EMBO Mol Med 2022. [DOI: 10.15252/emmm.202216301] [Reference Citation Analysis]
16 Huang X, Kong N, Zhang X, Cao Y, Langer R, Tao W. The landscape of mRNA nanomedicine. Nat Med 2022. [DOI: 10.1038/s41591-022-02061-1] [Reference Citation Analysis]
17 Hashiba K, Sato Y, Taguchi M, Sakamoto S, Otsu A, Maeda Y, Shishido T, Murakawa M, Okazaki A, Harashima H. Branching Ionizable Lipids Can Enhance the Stability, Fusogenicity, and Functional Delivery of mRNA. Small Science 2022. [DOI: 10.1002/smsc.202200071] [Reference Citation Analysis]
18 Mai D, June CH, Sheppard NC. In vivo gene immunotherapy for cancer. Sci Transl Med 2022;14. [DOI: 10.1126/scitranslmed.abo3603] [Reference Citation Analysis]
19 Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nat Biotechnol 2022. [DOI: 10.1038/s41587-022-01491-z] [Reference Citation Analysis]
20 Menasché P. Immunothérapie par CAR-T cells : du traitement des hémopathies malignes à celui des maladies cardiaques ? Bulletin de l'Académie Nationale de Médecine 2022. [DOI: 10.1016/j.banm.2022.10.012] [Reference Citation Analysis]
21 Lee S, Khalil AS, Wong WW. Recent progress of gene circuit designs in immune cell therapies. Cell Systems 2022;13:864-873. [DOI: 10.1016/j.cels.2022.09.006] [Reference Citation Analysis]
22 Chen Z, Meng C, Mai J, Liu Y, Li H, Shen H. An mRNA vaccine elicits STING-dependent antitumor immune responses. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.11.013] [Reference Citation Analysis]
23 Jiang K, Koob J, Chen XD, Krajeski RN, Zhang Y, Volf V, Zhou W, Sgrizzi SR, Villiger L, Gootenberg JS, Chen F, Abudayyeh OO. Programmable eukaryotic protein synthesis with RNA sensors by harnessing ADAR. Nat Biotechnol 2022. [DOI: 10.1038/s41587-022-01534-5] [Reference Citation Analysis]
24 Cao H, Gao S, Jogani R, Sugimura R. The Tumor Microenvironment Reprograms Immune Cells. Cellular Reprogramming 2022. [DOI: 10.1089/cell.2022.0047] [Reference Citation Analysis]
25 Abedini A, Ma Z, Frederick J, Dhillon P, Balzer MS, Shrestha R, Liu H, Vitale S, Devalaraja-narashimha K, Grandi P, Bhattacharyya T, Hu E, Pullen SS, Boustany-kari CM, Guarnieri P, Karihaloo A, Yan H, Coleman K, Palmer M, Sarov-blat L, Morton L, Hunter CA, Li M, Susztak K. Spatially resolved human kidney multi-omics single cell atlas highlights the key role of the fibrotic microenvironment in kidney disease progression.. [DOI: 10.1101/2022.10.24.513598] [Reference Citation Analysis]
26 Micheletti R, Alexanian M. Transcriptional plasticity of fibroblasts in heart disease. Biochemical Society Transactions 2022. [DOI: 10.1042/bst20210864] [Reference Citation Analysis]
27 Wallon L, Khan I, Teng KW, Koide A, Zuberi M, Li J, Ketavarapu G, Traaseth NJ, O'Bryan JP, Koide S. Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket. Proc Natl Acad Sci U S A 2022;119:e2204481119. [PMID: 36252024 DOI: 10.1073/pnas.2204481119] [Reference Citation Analysis]
28 Xue E, Minniti A, Alexander T, Del Papa N, Greco R, of the Ebmt OBOTADWP. Cellular-Based Therapies in Systemic Sclerosis: From Hematopoietic Stem Cell Transplant to Innovative Approaches. Cells 2022;11:3346. [DOI: 10.3390/cells11213346] [Reference Citation Analysis]
29 Mashima R, Takada S. Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application. Curr Issues Mol Biol 2022;44:5013-27. [PMID: 36286056 DOI: 10.3390/cimb44100341] [Reference Citation Analysis]
30 Guerriaud M, Kohli E. RNA-based drugs and regulation: Toward a necessary evolution of the definitions issued from the European union legislation. Front Med 2022;9:1012497. [DOI: 10.3389/fmed.2022.1012497] [Reference Citation Analysis]
31 Morfino P, Aimo A, Castiglione V, Gálvez-Montón C, Emdin M, Bayes-Genis A. Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy. Heart Fail Rev 2022. [PMID: 36221014 DOI: 10.1007/s10741-022-10279-x] [Reference Citation Analysis]
32 Zhang X, Hai L, Gao Y, Yu G, Sun Y. Lipid nanomaterials-based RNA therapy and cancer treatment. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.10.004] [Reference Citation Analysis]
33 Packard RRS. Cardiac fibrosis in oncologic therapies. Current Opinion in Physiology 2022;29:100575. [DOI: 10.1016/j.cophys.2022.100575] [Reference Citation Analysis]
34 Hong CC. The grand challenge of discovering new cardiovascular drugs. Front Drug Discov 2022;2. [DOI: 10.3389/fddsv.2022.1027401] [Reference Citation Analysis]
35 Rao A, Stewart A, Eljalby M, Ramakrishnan P, Anderson LD, Awan FT, Chandra A, Vallabhaneni S, Zhang K, Zaha VG. Cardiovascular disease and chimeric antigen receptor cellular therapy. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.932347] [Reference Citation Analysis]
36 Zuo YH, Zhao XP, Fan XX. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor. Pharmacol Res 2022;184:106454. [PMID: 36115525 DOI: 10.1016/j.phrs.2022.106454] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Zadory M, Lopez E, Babity S, Gravel SP, Brambilla D. Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression. Biomater Sci 2022. [PMID: 36097955 DOI: 10.1039/d2bm00859a] [Reference Citation Analysis]
38 Duan Q, Hu T, Zhu Q, Jin X, Chi F, Chen X. How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development. Front Immunol 2022;13:974433. [DOI: 10.3389/fimmu.2022.974433] [Reference Citation Analysis]
39 Sobecki M, Chen J, Krzywinska E, Nagarajan S, Fan Z, Nelius E, Monné Rodriguez JM, Seehusen F, Hussein A, Moschini G, Hajam EY, Kiran R, Gotthardt D, Debbache J, Badoual C, Sato T, Isagawa T, Takeda N, Tanchot C, Tartour E, Weber A, Werner S, Loffing J, Sommer L, Sexl V, Münz C, Feghali-Bostwick C, Pachera E, Distler O, Snedeker J, Jamora C, Stockmann C. Vaccination-based immunotherapy to target profibrotic cells in liver and lung. Cell Stem Cell 2022:S1934-5909(22)00376-9. [PMID: 36113462 DOI: 10.1016/j.stem.2022.08.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Zhang C, Zhang B. RNA therapeutics: updates and future potential. Sci China Life Sci 2022. [DOI: 10.1007/s11427-022-2171-2] [Reference Citation Analysis]
41 Cai Y, Song W, Li J, Jing Y, Liang C, Zhang L, Zhang X, Zhang W, Liu B, An Y, Li J, Tang B, Pei S, Wu X, Liu Y, Zhuang C, Ying Y, Dou X, Chen Y, Xiao F, Li D, Yang R, Zhao Y, Wang Y, Wang L, Li Y, Ma S, Wang S, Song X, Ren J, Zhang L, Wang J, Zhang W, Xie Z, Qu J, Wang J, Xiao Y, Tian Y, Wang G, Hu P, Ye J, Sun Y, Mao Z, Kong Q, Liu Q, Zou W, Tian X, Xiao Z, Liu Y, Liu J, Song M, Han JJ, Liu G. The landscape of aging. Sci China Life Sci 2022. [DOI: 10.1007/s11427-022-2161-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Tzahor E, Dimmeler S. A coalition to heal-the impact of the cardiac microenvironment. Science 2022;377:eabm4443. [PMID: 36048959 DOI: 10.1126/science.abm4443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Sánchez Martínez D, Tirado N, Mensurado S, Martínez-Moreno A, Romecín P, Gutiérrez Agüera F, Correia DV, Silva-Santos B, Menéndez P. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia. J Immunother Cancer 2022;10:e005400. [PMID: 36162920 DOI: 10.1136/jitc-2022-005400] [Reference Citation Analysis]
44 Speidel AT, Grigsby CL, Stevens MM. Ascendancy of semi-synthetic biomaterials from design towards democratization. Nat Mater 2022. [PMID: 36002728 DOI: 10.1038/s41563-022-01348-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Gao CA, Morales-nebreda L, Pickens CI. Gearing up for battle: Harnessing adaptive T cell immunity against gram-negative pneumonia. Front Cell Infect Microbiol 2022;12:934671. [DOI: 10.3389/fcimb.2022.934671] [Reference Citation Analysis]
46 Li C, Liu Z, Zhou Y. CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements. HSET 2022;8:54-63. [DOI: 10.54097/hset.v8i.1110] [Reference Citation Analysis]
47 Jie J, Mao D, Cao J, Feng P, Yang P. Customized Multifunctional Peptide Hydrogel Scaffolds for CAR-T-Cell Rapid Proliferation and Solid Tumor Immunotherapy. ACS Appl Mater Interfaces 2022. [PMID: 35944246 DOI: 10.1021/acsami.2c10727] [Reference Citation Analysis]
48 Dong Y, Peng N, Dong L, Tan S, Zhang X. Non-coding RNAs: Important participants in cardiac fibrosis. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.937995] [Reference Citation Analysis]
49 Tanaka H, Sakurai Y, Akita H. Lipid nanoparticles for mRNA delivery. Official Journal of the Japan Society of Drug Delivery System 2022;37:237-246. [DOI: 10.2745/dds.37.237] [Reference Citation Analysis]
50 Laskowski TJ, Biederstädt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer 2022. [PMID: 35879429 DOI: 10.1038/s41568-022-00491-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
51 Mashima R, Nakanishi M. Mammalian Sulfatases: Biochemistry, Disease Manifestation, and Therapy. IJMS 2022;23:8153. [DOI: 10.3390/ijms23158153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Raguram A, Banskota S, Liu DR. Therapeutic in vivo delivery of gene editing agents. Cell 2022;185:2806-27. [PMID: 35798006 DOI: 10.1016/j.cell.2022.03.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
53 Kularatne RN, Crist RM, Stern ST. The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery. Pharmaceuticals 2022;15:897. [DOI: 10.3390/ph15070897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
54 Beydoun N, Feinstein MJ. Heart Failure in Chronic Infectious and Inflammatory Conditions: Mechanistic Insights from Clinical Heterogeneity. Curr Heart Fail Rep 2022. [PMID: 35838874 DOI: 10.1007/s11897-022-00560-3] [Reference Citation Analysis]
55 Huston P. A Sedentary and Unhealthy Lifestyle Fuels Chronic Disease Progression by Changing Interstitial Cell Behaviour: A Network Analysis. Front Physiol 2022;13:904107. [DOI: 10.3389/fphys.2022.904107] [Reference Citation Analysis]
56 Stein-Merlob AF, Ganatra S, Yang EH. T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies. Heart Fail Clin 2022;18:443-54. [PMID: 35718418 DOI: 10.1016/j.hfc.2022.02.008] [Reference Citation Analysis]
57 Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. The Past, Present, and Future of Non-Viral CAR T Cells. Front Immunol 2022;13:867013. [PMID: 35757746 DOI: 10.3389/fimmu.2022.867013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Ciucci G, Colliva A, Vuerich R, Pompilio G, Zacchigna S. Biologics and cardiac disease: challenges and opportunities. Trends Pharmacol Sci 2022:S0165-6147(22)00128-6. [PMID: 35779965 DOI: 10.1016/j.tips.2022.06.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Schoutrop E, Renken S, Micallef Nilsson I, Hahn P, Poiret T, Kiessling R, Wickström SL, Mattsson J, Magalhaes I. Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality. OncoImmunology 2022;11:2093426. [DOI: 10.1080/2162402x.2022.2093426] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Testa S, Haabeth OAW, Blake TR, Del Castillo TJ, Czerwinski DK, Rajapaksa R, Wender PA, Waymouth RM, Levy R. Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro. Biomacromolecules 2022. [PMID: 35748182 DOI: 10.1021/acs.biomac.2c00469] [Reference Citation Analysis]
61 Weiß E, Ramos GC, Delgobo M. Myocardial-Treg Crosstalk: How to Tame a Wolf. Front Immunol 2022;13:914033. [PMID: 35693830 DOI: 10.3389/fimmu.2022.914033] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Hartweger H, Nussenzweig MC. CRISPR comes a-knock-in to reprogram antibodies in vivo. Nat Biotechnol 2022. [PMID: 35681058 DOI: 10.1038/s41587-022-01299-x] [Reference Citation Analysis]
63 Nahmad AD, Lazzarotto CR, Zelikson N, Kustin T, Tenuta M, Huang D, Reuveni I, Nataf D, Raviv Y, Horovitz-Fried M, Dotan I, Carmi Y, Rosin-Arbesfeld R, Nemazee D, Voss JE, Stern A, Tsai SQ, Barzel A. In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nat Biotechnol 2022. [PMID: 35681059 DOI: 10.1038/s41587-022-01328-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Peruzzi JA, Steinkühler J, Vu TQ, Gunnels TF, Lu P, Baker D, Kamat NP. Hydrophobic mismatch drives self-organization of designer proteins into synthetic membranes.. [DOI: 10.1101/2022.06.01.494374] [Reference Citation Analysis]
65 Thackeray JT, Hess A. Good Things in Small Packages: Growth and Potential of Theragnostic Platforms in Cardiovascular Medicine. Circ Cardiovasc Imaging 2022;15:e014403. [PMID: 35678175 DOI: 10.1161/CIRCIMAGING.122.014403] [Reference Citation Analysis]
66 Choudhary MC, Cyktor JC, Riddler SA. Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir. Journal of Virus Eradication 2022;8:100073. [DOI: 10.1016/j.jve.2022.100073] [Reference Citation Analysis]
67 Tharp CA, McKinsey TA. Tissue is the issue: Endomyocardial biopsies to elucidate molecular mechanisms and tailor therapy for HFpEF. J Mol Cell Cardiol 2022;169:111-2. [PMID: 35660295 DOI: 10.1016/j.yjmcc.2022.05.008] [Reference Citation Analysis]
68 Zhang Q, Zu C, Hu Y, Huang H. CAR-T cells for cancer immunotherapy-the barriers ahead and the paths through. Int Rev Immunol 2022;:1-15. [PMID: 35635212 DOI: 10.1080/08830185.2022.2080820] [Reference Citation Analysis]
69 Barros LRC, Couto SCF, da Silva Santurio D, Paixão EA, Cardoso F, da Silva VJ, Klinger P, Ribeiro PDAC, Rós FA, Oliveira TGM, Rego EM, Ramos RN, Rocha V. Systematic Review of Available CAR-T Cell Trials around the World. Cancers 2022;14:2667. [DOI: 10.3390/cancers14112667] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
70 Cheng MHY, Brimacombe CA, Verbeke R, Cullis PR. Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies. Mol Pharm 2022. [PMID: 35583489 DOI: 10.1021/acs.molpharmaceut.2c00365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Stranford DM, Simons LM, Berman KE, Cheng L, Lucks JB, Hultquist JF, Leonard JN. Bioengineering multifunctional extracellular vesicles for targeted delivery of biologics to T cells.. [DOI: 10.1101/2022.05.14.491879] [Reference Citation Analysis]
72 Zhong G, Luo Y, Zhao J, Wang M, Yang F, Huang J, Zou L, Zou X, Wang Q, Chen F, Wang G, Yu Y. Highly efficient healing of critical sized articular cartilage defect in situ using a chemically nucleoside-modified mRNA-enhanced cell therapy.. [DOI: 10.1101/2022.05.06.490932] [Reference Citation Analysis]
73 Wong A, Hamidzada H, Epelman S. A cardioimmunologist's toolkit: genetic tools to dissect immune cells in cardiac disease. Nat Rev Cardiol 2022. [PMID: 35523863 DOI: 10.1038/s41569-022-00701-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
74 Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J 2022:ehac223. [PMID: 35511857 DOI: 10.1093/eurheartj/ehac223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
75 Tao X, Zhang R, Du R, Yu T, Yang H, Li J, Wang Y, Liu Q, Zuo S, Wang X, Lazarus M, Zhou L, Wang B, Yu Y, Shen Y. EP3 enhances adhesion and cytotoxicity of NK cells toward hepatic stellate cells in a murine liver fibrosis model. J Exp Med 2022;219:e20212414. [PMID: 35420633 DOI: 10.1084/jem.20212414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
76 Prakash G, Shokr A, Willemen N, Bashir SM, Shin SR, Hassan S. Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids. Adv Drug Deliv Rev 2022;184:114197. [PMID: 35288219 DOI: 10.1016/j.addr.2022.114197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
77 Qu G, Chen J, Li Y, Yuan Y, Liang R, Li B. Current status and perspectives of regulatory T cell-based therapy. Journal of Genetics and Genomics 2022. [DOI: 10.1016/j.jgg.2022.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Anto Michel N, Ljubojevic-holzer S, Bugger H, Zirlik A. Cellular Heterogeneity of the Heart. Front Cardiovasc Med 2022;9:868466. [DOI: 10.3389/fcvm.2022.868466] [Reference Citation Analysis]
79 He X, Du T, Long T, Liao X, Dong Y, Huang ZP. Signaling cascades in the failing heart and emerging therapeutic strategies. Signal Transduct Target Ther 2022;7:134. [PMID: 35461308 DOI: 10.1038/s41392-022-00972-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
80 Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nat Med 2022;28:678-89. [PMID: 35440724 DOI: 10.1038/s41591-022-01765-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
81 Friedman SL. Fighting Cardiac Fibrosis with CAR T Cells. N Engl J Med 2022;386:1576-8. [PMID: 35443114 DOI: 10.1056/NEJMcibr2201182] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
82 Lu R, Liang K, Chiang H, Hsu F, Lin H, Chen W, Ke F, Kumari M, Chou Y, Wu H. Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice.. [DOI: 10.1101/2022.04.19.488843] [Reference Citation Analysis]
83 Rurik JG, Epstein JA. Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune System In Vivo to Treat Heart Disease. DNA Cell Biol 2022. [PMID: 35446147 DOI: 10.1089/dna.2022.0171] [Reference Citation Analysis]
84 Simões FC, Riley PR. Immune cells in cardiac repair and regeneration. Development 2022;149:dev199906. [PMID: 35502777 DOI: 10.1242/dev.199906] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
85 Shi HT, Huang ZH, Xu TZ, Sun AJ, Ge JB. New diagnostic and therapeutic strategies for myocardial infarction via nanomaterials. EBioMedicine 2022;78:103968. [PMID: 35367772 DOI: 10.1016/j.ebiom.2022.103968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
86 Bowers SLK, Meng Q, Molkentin JD. Fibroblasts orchestrate cellular crosstalk in the heart through the ECM. Nat Cardiovasc Res 2022;1:312-321. [DOI: 10.1038/s44161-022-00043-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
87 Booz GW, Altara R, Zouein FA. Editorial: Immunomodulatory Approaches in Cardiovascular Diseases. Front Cardiovasc Med 2022;9:873452. [DOI: 10.3389/fcvm.2022.873452] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Shi J, Huang MW, Lu ZD, Du XJ, Shen S, Xu CF, Wang J. Delivery of mRNA for regulating functions of immune cells. J Control Release 2022:S0168-3659(22)00159-6. [PMID: 35337940 DOI: 10.1016/j.jconrel.2022.03.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
89 Sánchez-martínez D, Tirado N, Mensurado S, Martínez-moreno A, Romecin P, Gutiérrez-agüera F, Correia DV, Silva-santos B, Menéndez P. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid Leukemia.. [DOI: 10.1101/2022.03.15.484289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Vagnozzi RJ, McKinsey TA. T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR. Cell Stem Cell 2022;29:352-4. [PMID: 35245466 DOI: 10.1016/j.stem.2022.02.002] [Reference Citation Analysis]
91 Aghajanian H, Rurik JG, Epstein JA. CAR-based therapies: opportunities for immuno-medicine beyond cancer. Nat Metab 2022;4:163-9. [PMID: 35228742 DOI: 10.1038/s42255-022-00537-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
92 Dürschmied D, Hilgendorf I, Kohl P, Rog-zielinska E, Verheyen J. Sonderforschungsbereich (SFB) 1425 – Die heterozelluläre Natur kardialer Läsionen. Kardiologe 2022;16:128-135. [DOI: 10.1007/s12181-022-00541-9] [Reference Citation Analysis]
93 Liao Z, Zhang W, Zheng H, Wang Y, Yu J, Li H, Gu Z. Leveraging biomaterials for enhancing T cell immunotherapy. J Control Release 2022:S0168-3659(22)00097-9. [PMID: 35217099 DOI: 10.1016/j.jconrel.2022.02.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
94 Dilliard SA, Siegwart DJ. Disrupting off-target Cas9 activity in the liver. Nat Biomed Eng. [DOI: 10.1038/s41551-022-00848-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Villanueva MT. Repairing cardiac injury with transient CAR-T cells. Nat Rev Drug Discov. [DOI: 10.1038/d41573-022-00024-2] [Reference Citation Analysis]
96 Ledford H. Last-resort cancer therapy holds back disease for more than a decade. Nature 2022. [PMID: 35110708 DOI: 10.1038/d41586-022-00241-0] [Reference Citation Analysis]
97 Campos Ramos G, Hudecek M. The era of in vivo T cell engineering. Med 2022;3:85-6. [DOI: 10.1016/j.medj.2022.01.012] [Reference Citation Analysis]
98 Jiang K, Koob J, Chen XD, Krajeski RN, Zhang Y, Villiger L, Zhou W, Abudayyeh OO, Chen F, Gootenberg JS. Programmable eukaryotic protein expression with RNA sensors.. [DOI: 10.1101/2022.01.26.477951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Clyde D. Fighting fibrosis with transient CAR T cells. Nat Rev Genet 2022. [PMID: 35064237 DOI: 10.1038/s41576-022-00450-3] [Reference Citation Analysis]
100 Gao TA, Chen YY. T cells to fix a broken heart. Science 2022;375:23-4. [PMID: 34990255 DOI: 10.1126/science.abn0851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Li M, Wang Z, Xie C, Xia X. Advances in mRNA vaccines. mRNA-Based Therapeutics 2022. [DOI: 10.1016/bs.ircmb.2022.04.011] [Reference Citation Analysis]
102 Geddie ML, Kirpotin DB, Kohli N, Kornaga T, Boll B, Razlog M, Drummond DC, Lugovskoy AA. Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics. MAbs 2022;14:2083466. [PMID: 35708974 DOI: 10.1080/19420862.2022.2083466] [Reference Citation Analysis]
103 Yu J, Li T, Zhu J. Gene Therapy Strategies Targeting Aging-Related Diseases. Aging and disease 2022. [DOI: 10.14336/ad.2022.00725] [Reference Citation Analysis]
104 Zhao† Z, Deng† S, Wang Q, Jia C, Yang J. Novel Insight into Blocking Cancer Metastasis by Biological Nano Confinement through Altering the Cancer Microenvironment. Clin Cancer Investig J 2022;11:10-14. [DOI: 10.51847/0ozasxscb1] [Reference Citation Analysis]